The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The closing price of Avidity Biosciences Inc (NASDAQ: RNA) was $32.61 for the day, up 10.24% from the previous closing price of $29.58. In other words, the price has increased by $10.24 from its previous closing price. On the day, 1.31 million shares were traded. RNA stock price reached its highest trading level at $32.69 during the session, while it also had its lowest trading level at $30.68.
Ratios:
Our analysis of RNA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 15.73 and its Current Ratio is at 15.73. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BMO Capital Markets on Mar-13-25, initiated with a Outperform rating and assigned the stock a target price of $72.
On March 07, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $70.
On December 20, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $72.H.C. Wainwright initiated its Buy rating on December 20, 2024, with a $72 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 11 ’25 when Flanagan W. Michael sold 20,000 shares for $30.13 per share. The transaction valued at 602,614 led to the insider holds 91,975 shares of the business.
WILLIAM MICHAEL FLANAGAN bought 20,000 shares of RNA for $600,800 on Mar 11 ’25. On Mar 03 ’25, another insider, Gallagher Kathleen P., who serves as the Chief Program Officer of the company, sold 5,875 shares for $29.41 each. As a result, the insider received 172,807 and left with 50,554 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 3920113408 and an Enterprise Value of 2061183872. For the stock, the TTM Price-to-Sale (P/S) ratio is 359.64 while its Price-to-Book (P/B) ratio in mrq is 2.74. Its current Enterprise Value per Revenue stands at 189.151 whereas that against EBITDA is -5.48.
Stock Price History:
The Beta on a monthly basis for RNA is 1.00, which has changed by 0.3604505 over the last 52 weeks, in comparison to a change of 0.087141395 over the same period for the S&P500. Over the past 52 weeks, RNA has reached a high of $56.00, while it has fallen to a 52-week low of $20.91. The 50-Day Moving Average of the stock is 5.53%, while the 200-Day Moving Average is calculated to be -15.67%.
Shares Statistics:
RNA traded an average of 1.35M shares per day over the past three months and 1287950 shares per day over the past ten days. A total of 119.89M shares are outstanding, with a floating share count of 111.07M. Insiders hold about 7.61% of the company’s shares, while institutions hold 103.99% stake in the company. Shares short for RNA as of 1740700800 were 16954734 with a Short Ratio of 12.54, compared to 1738281600 on 14949939. Therefore, it implies a Short% of Shares Outstanding of 16954734 and a Short% of Float of 17.36.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
